Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation

Seminars in Radiation Oncology

Volumn 11, Issue 1, 2001, Pages 47-57

  Chapman, J Donald ^a   Schneider, Richard F ^a   Urbain, Jean Luc ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; CHELATING AGENT; CHEMICAL AGENT; COPPER CHELATE; ISOTOPE; METAL; OXYGEN 15; RADIOACTIVE MATERIAL; TECHNETIUM; TUMOR MARKER; UNCLASSIFIED DRUG;

BRAIN PERFUSION; CANCER; COVALENT BOND; DIAGNOSTIC IMAGING; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; ONCOLOGY; OXYGEN TISSUE LEVEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TREATMENT PLANNING; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 0035177313     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.18103     Document Type: Article

References (71)

1. Conclusions: Prediction of tumor treatment response
2. 15O and positron emission tomography: Analytical techniques and preliminary results
3. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole
4. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells
5. A marker for hypoxic cells in tumors with potential clinical applicability
6. 14C-misonidazole
7. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours
8. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3,-pentafluoropropyl)acetamide]: Analysis of drug adducts by fluorescent antibodies vs. bound radioactivity
9. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors
10. Measurement of hypoxia in human tumors by SPECT imaging of iodoazomcyin arabinoside
11. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography
12. Positron emission tomography for in-vivo measurement of regional flow, oxygen utilisation and blood volume in patients with breast carcinoma
13. Some biological aspects of soft tissue tumors as studied by PET
14. PET study of changes in local brain hemodynamics and oxygen metabolism after unilateral middle cerebral artery occlusion in baboons
15. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia
16. Using the spleen for time-delay correction of the input function in measuring hepatic blood flow with oxygen-15 water by dynamic PET
17. Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET
18. Nitrogen-13-ammonia and oxygen-15-water estimates of absolute myocardial perfusion in left ventricular ischemic dysfunctlon
19. Tumor blood flow measured using dynamic computed tomography
20. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography
21. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma
22. 15O decay studies of tumor blood flow
23. 15O photon activation for the measurement of tumor perfusion using an Elekta SL25
24. Rapid algorithms for the construction of cerebral blood flow and oxygen utilization images with oxygen-15 and dynamic positron emission tomography
25. Angiotensin-II-induced hypertension chemotherapy: Evaluation of hepatic blood flow with oxygen-15 PET
26. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays
27. Preclinical assessment of hypoxic marker specificity and sensitivity
28. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles
29. Studies on the radiosensitizing effect of oxygen in Chinese hamster cells
30. Adduct formation by 2-nitroimidazole drugs in mammalian cells: Optimization of markers for tissue oxygenation
31. The synthesis and radiolabeling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class
32. Radiopharmaceuticals for imaging hypoxia
33. 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection
34. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy
35. 2?
36. Prediction of tumor hypoxia and radioresistance with nuclear medicine markers
37. 123I-Iodoazomycin arabinoside: Preliminary report of a clinical study
38. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
39. Nitroimidazoles and imaging hypoxia
40. Technetium labelled agents for imaging tissue hypoxia in vivo
41. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS-181321) as a marker of tumor hypoxia
42. Noninvasive monitoring of photodynamic therapy with Technetium HMPAO scintigraphy
43. The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas
44. Applicability of 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia
45. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG
46. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential
47. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model
48. Oxygenation of human tumors: The Mainz experience
49. Marking hypoxia in rat prostate carcinomas with β-D-(I-125) AZGP and (Tc-99m) HL-91: Correlation with microelectrode measurements
50. Relationship between radiobiological hypoxia and direct estimates of tumor oxygenation in a mouse tumour model
51. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: Accuracy and reproducibility
52. Tumor hypoxia: Its impact on cancer therapy
53. The cellular basis of radiotherapeutic response
54. Changes in misonidazole binding with hypoxic fraction in mouse tumors
55. NMR spectroscopy and sensitizer-adduct measurements of PDT-induced ischemia in solid tumors
56. 3H] misonidazole binding and paired survival assay
57. Performance evaluation of microPET: A high-resolution lutetium oxyorthosilicate PET scanner for animal imaging
58. Ultra-high-resolution imaging of small animals: Implications for preclinical and research studies
59. Positron-emission tomographic imaging of cancer: Glucose metabolism and beyond
60. 124I]iododeoxyuridine
61. Condensed chromatin and cell inactivation by single-hit kinetics
62. Resolution of kinase activities during the HeLa cell cycle: Identification of kinases with cyclic activities
63. Mitotic chromosome condensation
64. 2 predicts survival in advanced cancer of the uterine cervix
65. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of head and neck
66. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
67. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
68. Oxygenation predicts radiation response and survival in patients with cervix cancer
69. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: Results from the EORTC cooperative trial 22851
70. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix
71. 2) is a prognostic factor for local control in head and neck cancers